Home/Filings/4/0001209191-23-017148
4//SEC Filing

Simon Farrell 4

Accession 0001209191-23-017148

CIK 0001563880other

Filed

Mar 7, 7:00 PM ET

Accepted

Mar 8, 4:00 PM ET

Size

7.1 KB

Accession

0001209191-23-017148

Insider Transaction Report

Form 4
Period: 2023-03-07
Simon Farrell
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2023-03-0718,75056,250 total
    Exercise: $0.51Exp: 2032-02-10Common Stock (18,750 underlying)
  • Exercise/Conversion

    Common Stock

    2023-03-07$0.51/sh+18,750$9,58139,400 total
Footnotes (1)
  • [F1]This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

Issuer

Trevi Therapeutics, Inc.

CIK 0001563880

Entity typeother

Related Parties

1
  • filerCIK 0001965585

Filing Metadata

Form type
4
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 4:00 PM ET
Size
7.1 KB